Related Experiment Video

Updated: Aug 20, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
06:39

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

Published on: August 18, 2016

Effect of azithromycin therapy on coronary circulation in patients with coronary artery disease

Eiichi Hyodo1, Takeshi Hozumi, Yasuhiko Takemoto

  • 1Department of Internal Medicine and Cardiology, Osaka City University School of Medicine, Osaka, Japan.

The American Journal of Cardiology
|November 30, 2004
PubMed

Insights

Azithromycin therapy improved coronary microcirculation in patients with coronary artery disease. This was measured by coronary flow velocity reserve (CFVR), showing significant enhancement after treatment.

Area of Science:

  • Cardiology
  • Pharmacology
  • Microcirculation

Background:

  • Coronary artery disease (CAD) affects microvascular function.
  • Inflammation plays a role in CAD progression.
  • Azithromycin is an antibiotic with potential anti-inflammatory properties.

Purpose of the Study:

  • To investigate the impact of azithromycin on coronary microcirculation.
  • To assess changes in coronary flow velocity reserve (CFVR) following azithromycin therapy.
  • To explore the relationship between CFVR changes and inflammatory markers.

Main Methods:

  • Study included 35 patients diagnosed with coronary artery disease.
  • Coronary flow velocity reserve (CFVR) was measured using transthoracic Doppler echocardiography.
  • High-sensitivity C-reactive protein (hs-CRP) levels were monitored.

Main Results:

  • A statistically significant increase in CFVR was observed post-azithromycin therapy (3.0 +/- 0.7 to 3.5 +/- 0.7, p <0.001).
  • The improvement in CFVR was inversely correlated with reductions in hs-CRP levels.
  • Azithromycin demonstrated a positive effect on coronary microvascular function.

Conclusions:

  • Azithromycin therapy can enhance coronary microcirculation in patients with CAD.
  • The beneficial effects may be linked to azithromycin's anti-inflammatory actions.
  • Further research is warranted to confirm these findings and explore clinical implications.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...